Legend Biotech Corporation
LEGN
Rang in Aktien
#4424
Legend Biotech Corporation, through its subsidiaries, operates as a... Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
Aktienkurs
$19.04
Marktkapitalisierung
$3.52B
Veränderung (1 Tag)
2.09%
Veränderung (1 Jahr)
-42.15%
Land
US
Handel Legend Biotech Corporation (LEGN)
Kategorie
Healthcare
Anzahl der ausstehenden Aktien von Legend Biotech Corporation (LEGN)
Anzahl der ausstehenden Aktien zum June 2026: 187.00M
Laut den neuesten Finanzberichten und dem Aktienkurs von Legend Biotech Corporation beträgt die aktuelle Anzahl der ausstehenden Aktien 187.00M. Am Ende von December 2023 hatte das Unternehmen 88.04M ausstehende Aktien. Die Anzahl der ausstehenden Aktien wird normalerweise durch Aktiensplits und Aktienrückkäufe beeinflusst.
Verlauf der ausstehenden Aktien von Legend Biotech Corporation (LEGN) von 2017 bis 2026
Ausstehende Aktien am Ende jedes Jahres
| Jahr | Ausstehende Aktien | ändert |
|---|---|---|
| 2026 (TTM) | 187.00M | 104.54% |
| 2024 | 91.43M | 3.84% |
| 2023 | 88.04M | 10.71% |
| 2022 | 79.52M | 12.91% |
| 2021 | 70.43M | 19.21% |
| 2020 | 59.08M | -10.49% |
| 2019 | 66.00M | 32.01% |
| 2018 | 50.00M | -24.25% |
| 2017 | 66.00M | 0.00% |
Ausstehende Aktien bei ähnlichen Unternehmen oder Wettbewerbern
| Unternehmen | Ausstehende Aktien | Unterschied | Land |
|---|---|---|---|
| 253.90M | 35.78% |
US
|
|
| 396.00M | 111.76% |
US
|
|
| 478.91M | 156.10% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -66.75% |
NL
|
